These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11971868)

  • 1. Gene expression profiles of poor-prognosis primary breast cancer correlate with survival.
    Bertucci F; Nasser V; Granjeaud S; Eisinger F; Adelaïde J; Tagett R; Loriod B; Giaconia A; Benziane A; Devilard E; Jacquemier J; Viens P; Nguyen C; Birnbaum D; Houlgatte R
    Hum Mol Genet; 2002 Apr; 11(8):863-72. PubMed ID: 11971868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling of primary breast carcinomas using arrays of candidate genes.
    Bertucci F; Houlgatte R; Benziane A; Granjeaud S; Adélaïde J; Tagett R; Loriod B; Jacquemier J; Viens P; Jordan B; Birnbaum D; Nguyen C
    Hum Mol Genet; 2000 Dec; 9(20):2981-91. PubMed ID: 11115842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classification of human breast cancer using gene expression profiling as a component of the survival predictor algorithm.
    Glinsky GV; Higashiyama T; Glinskii AB
    Clin Cancer Res; 2004 Apr; 10(7):2272-83. PubMed ID: 15073102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome.
    Bergamaschi A; Tagliabue E; Sørlie T; Naume B; Triulzi T; Orlandi R; Russnes HG; Nesland JM; Tammi R; Auvinen P; Kosma VM; Ménard S; Børresen-Dale AL
    J Pathol; 2008 Feb; 214(3):357-67. PubMed ID: 18044827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
    Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
    Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis of breast cancer and gene expression profiling using DNA arrays.
    Bertucci F; Houlgatte R; Granjeaud S; Nasser V; Loriod B; Beaudoing E; Hingamp P; Jacquemier J; Viens P; Birnbaum D; Nguyen C
    Ann N Y Acad Sci; 2002 Dec; 975():217-31. PubMed ID: 12538167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer.
    Savci-Heijink CD; Halfwerk H; Koster J; Van de Vijver MJ
    BMC Cancer; 2017 Nov; 17(1):755. PubMed ID: 29132326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis.
    Jacquemier J; Ginestier C; Rougemont J; Bardou VJ; Charafe-Jauffret E; Geneix J; Adélaïde J; Koki A; Houvenaeghel G; Hassoun J; Maraninchi D; Viens P; Birnbaum D; Bertucci F
    Cancer Res; 2005 Feb; 65(3):767-79. PubMed ID: 15705873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and clinical validation of a multigene assay that interrogates the biology of cancer stem cells and predicts metastasis in breast cancer: A retrospective consecutive study.
    Pece S; Disalvatore D; Tosoni D; Vecchi M; Confalonieri S; Bertalot G; Viale G; Colleoni M; Veronesi P; Galimberti V; Di Fiore PP
    EBioMedicine; 2019 Apr; 42():352-362. PubMed ID: 30846393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.
    Wang Y; Klijn JG; Zhang Y; Sieuwerts AM; Look MP; Yang F; Talantov D; Timmermans M; Meijer-van Gelder ME; Yu J; Jatkoe T; Berns EM; Atkins D; Foekens JA
    Lancet; 2005 Feb 19-25; 365(9460):671-9. PubMed ID: 15721472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer.
    Bertucci F; Borie N; Roche H; Bachelot T; Le Doussal JM; Macgrogan G; Debono S; Martinec A; Treilleux I; Finetti P; Esterni B; Extra JM; Geneve J; Hermitte F; Chabannon C; Jacquemier J; Martin AL; Longy M; Maraninchi D; Fert V; Birnbaum D; Viens P
    Breast Cancer Res Treat; 2011 Jun; 127(2):363-73. PubMed ID: 20585850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
    Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
    Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
    Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
    Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.
    Acharya CR; Hsu DS; Anders CK; Anguiano A; Salter KH; Walters KS; Redman RC; Tuchman SA; Moylan CA; Mukherjee S; Barry WT; Dressman HK; Ginsburg GS; Marcom KP; Garman KS; Lyman GH; Nevins JR; Potti A
    JAMA; 2008 Apr; 299(13):1574-87. PubMed ID: 18387932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.
    Oh DS; Troester MA; Usary J; Hu Z; He X; Fan C; Wu J; Carey LA; Perou CM
    J Clin Oncol; 2006 Apr; 24(11):1656-64. PubMed ID: 16505416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.
    Hartmann O; Spyratos F; Harbeck N; Dietrich D; Fassbender A; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Lerebours F; Welzel K; Maier S; Plum A; Niemann S; Foekens JA; Lesche R; Martens JW
    Clin Cancer Res; 2009 Jan; 15(1):315-23. PubMed ID: 19118060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response.
    Cameron DA; Gregory WM; Bowman A; Anderson ED; Levack P; Forouhi P; Leonard RC
    Br J Cancer; 2000 Jul; 83(1):98-103. PubMed ID: 10883676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
    Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
    Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.